- Research article
- Open Access
Gene transfer of Hodgkin cell lines via multivalent anti-CD30 scFv displaying bacteriophage
© Chung et al; licensee BioMed Central Ltd. 2008
- Received: 27 June 2007
- Accepted: 16 April 2008
- Published: 16 April 2008
The display of binding ligands, such as recombinant antibody fragments, on the surface of filamentous phage makes it possible to specifically attach these phage particles to target cells. After uptake of the phage, their internal single-stranded DNA is processed by the host cell, which allows transient expression of an encoded eukaryotic gene cassette. This opens the possibility to use bacteriophage as vectors for targeted gene therapy, although the transduction efficiency is very low.
Here we demonstrate the display of an anti-CD30 single chain variable fragment fused to the major coat protein pVIII on the surface of bacteriophage. These phage particles showed an improved binding and transduction efficiency of CD30 positive Hodgkin-lymphoma cells, compared to bacteriophage with the anti-CD30 single chain variable fragment fused to the minor coat protein pIII.
We can conclude from the results that the postulated multivalency of the anti-CD30-pVIII displaying bacteriophage combined with disseminated display of the anti-CD30 scFv on the whole particle surface is responsible for the improved gene transfer rate. These results mark an important step towards the use of phage particles as a cheap and safe gene transfer vehicle for the gene delivery of the desired target cells via their specific surface receptors.
- Coat Protein
- Phage Particle
- Transduction Efficiency
- Helper Phage
- Multiple Myeloma Cell Line
The specific in or ex vivo transduction of cancerous, infected or malfunctioning cells with pro-apoptotic, defence or restoring genes is a promising approach for the treatment of patients. However, gene therapy continues to present obstacles, regarding safety, transduction efficiency and specificity. Most gene delivery systems are based on animal viral vectors, which are efficient on one hand, but may include the risk of intrinsic toxicity and are costly to manufacture. In addition to developing safer viral vectors, scientists began modifying bacteriophage particles for gene delivery purposes [1, 2]. For example, filamentous bacteriophage libraries, consist of up to 1010 unique phage particles; each displaying a different binding ligand on its surface and encapsulating the corresponding eukaryotic cDNA. These libraries are commonly used for the selection of novel antigen-specific binding molecules. Furthermore, it is possible to select for ligand-bound phage being internalised by the target cell after receptor-binding [4, 5]. If a eukaryotic gene cassette is encoded in the phagemid vector, a small percentage of target cells will express this gene [2, 6, 7]. Thus, bacteriophage have the potential to serve as specifically targeted gene delivery vectors. They have no natural tropism for eukaryotic cells, nor do they integrate into the cell's genome.
A filamentous bacteriophage containing a phagemid vector (herein after referred to as "phagemid particle") encodes only the gene for a surface fusion protein, an antibiotic resistance gene and an amplification and packaging signal, but lacks the genes for all other bacteriophage proteins. In order to produce functional phagemid particles, E. coli transformed with the phagemid vector have to be superinfected with helper phage (phage rescue), which contribute the missing proteins for the phagemid particle assembly in the periplasm of E. coli. Phagemid particles are easy to genetically modify in terms of targeting to a specific receptor-bearing cell population. As phagemid vectors are relatively small in size compared to full size phage vectors, they are capable of carrying larger foreign DNA sequences. However, a major obstacle of using bacteriophage as gene transfer vehicles is their low transduction efficiency, which relies on gene transfer and expression. Gene transfer efficiency generally depends on the binding affinity of the ligand and the intracellular trafficking of the internalized receptor-bound phage, including endosomal escape and capsid breakdown. Moreover, processing of the single-stranded phage DNA, including conversion into double-stranded DNA and nuclear localization, is a critical factor .
Commonly, the displayed ligand is fused to the minor coat protein pIII (5 copies per phage). Ligands can be displayed either monovalently or multivalently, depending on the helper phage system being used. The importance of this factor has been demonstrated by Larocca et al. (2001)  in comparing the transduction efficiency of epidermal growth factor receptor (EGFR)-positive target cells with bacteriophage containing a green fluorescence protein (GFP) gene and displaying either monovalently or multivalently the EGF molecule. The multivalency of the EGF, fused to the minor coat protein pIII on the phage particles, increased transduction efficiency by 5-fold. Similar effects have been shown by Poul and Marks (1999) using a pIII-displayed anti-ErbB2 scFv.
Moreover, it has been demonstrated that phages displaying ligands fused to their major coat protein pVIII (2700 copies per phage) are able to bind to cell surface receptors, be internalized and processed inside mammalian cells  leading to marker gene expression . It is generally believed that the wild type to fusion protein ratio of pVIII displaying phage is inversely related to the size of the displayed ligand, making it difficult to functionally express larger proteins on the phage surface . Nevertheless, it has been shown that this correlation is not so stringent. Malik et al. (1996) demonstrated that Fab fragments and enzymes can be displayed on pVIII, but with a frequency of less than 1% .
We were interested in developing a gene delivery vector for the specific transduction of Hodgkin/Reed-Sternberg cells, the malignant cell type of Hodgkin's lymphoma. The CD30 receptor has been exploited as Hodgkin-lymphoma associated antigen in recent experimental therapeutic strategies [13, 14]. Antibodies bound to CD30 are internalized by clathrin-mediated endocytosis and traffic to the lysosome . Regarding this internal trafficking of CD30-bound complexes as a prerequisite for gene transfer, we generated a phagemid vector that encodes an anti-CD30 scFv-pVIII fusion protein and a eukaryotic CMV-EGFP gene cassette. Out of this vector we produced small, anti-CD30 phagemid particles, capable of delivering EGFP as a reporter gene for transduction. We chose the major coat protein pVIII as the fusion partner for the display of the anti-CD30 scFv Ki-4 . Fusion with pVIII as an alternative to the widely used minor coat protein pIII should increase the multivalency of the scFv-display and demonstrate the feasibility of displaying relatively big molecules, like scFvs (27 kDa) on pVIII.
Construction of the anti-CD30 gene transfer phagemid vectors
Detection of Ki-4 scFv fused to bacteriophage coat protein pVIII
Specific CD30 binding of Ki-4 scFv-displaying phage
Specific gene transfer of CD30-positive cells by targeted bacteriophage
Use of bacteriophage as vectors for targeted gene transfer into eukaryotic cells is an alternative method to circumvent some of the problems occurring with the established viral vectors. Bacteriophage have no natural tropism for eukaryotic cells but can be targeted towards specific cell surface receptors by displaying appropriate binding ligands, such as peptides or antibody fragments. Internalized by receptor-mediated endocytosis, their packaged single-stranded DNA is further processed (mechanisms not fully understood), leading to the expression of encoded genes under eukaryotic promoters . The ease with which one can target, modify, produce and purify these phage makes them a valuable tool for antigen-specific cell transduction. Here, we describe the generation of anti-CD30 targeted phagemid particles, specifically binding and transducing CD30-positive cells. For this purpose, the anti-CD30 Ki-4 scFv gene has been genetically fused either to the major coat protein pVIII (pAK8-Ki-4(EGFP)) or the minor coat protein pIII (pC6-Ki-4(EGFP)) in a phagemid vector, which also encodes an EGFP gene under the control of a CMV promoter. The expression of the Ki-4 scFv-pVIII fusion protein was determined by Western blot analysis (Fig. 2) and ELISA experiments with recombinant CD30 antigen demonstrating the specific binding of the Ki-4 scFv displaying phagemid particles (Fig. 3). Additionally, phage displaying the Ki-4 scFv showed a specific binding to CD30-bearing cells in FACS analyses. Binding affinity of the M13-pAK8-Ki-4(EGFP) phagemid particles to CD30 antigen and CD30 receptor-bearing cells was always higher, compared to the M13-pC6-Ki-4(EGFP) phagemid particles. Provided that scFvs fused to the pIII coat protein have the same binding affinity as pVIII-fusion proteins, this difference could be explained by a multivalent display of the anti-CD30 Ki-4 scFv on the M13-pAK8-Ki-4(EGFP) phagemid particles indicating a binding avidity effect. The multivalent display of the scFv on the M13-pAK8-Ki-4(EGFP) phagemid particles is also supported by the fact that these phagemid particles are able to induce additional cluster formation of CD30-positive cells (Fig. 5). This phenomena was not seen with the supplement of M13-pC6-Ki-4(EGFP) phagemid particles or the addition of the M13-pAK8-Ki-4(EGFP) phagemid particles to the CD30-negative cell line BL38, but has been observed previously by the addition of monoclonal Ki-4 IgG antibody to CD30-positive cells (data not shown).
The transduction experiments with different cell lines revealed that anti-CD30 scFv-displaying phagemid particles are able to transduce CD30 receptor-bearing cells. The addition of the parental monoclonal antibody Ki-4 significantly reduced the amount of CD30-positive L1236 cells transduced by the M13-pAK8-Ki-4(EGFP) phagemid particles (Fig. 6a). There was no unspecific transduction of CD30-negative cells, nor did control phagemid particles M13-pAK8(EGFP) transduce the CD30-positive cells (Fig. 6d). This indicates that CD30 antigen on the targeting cell lines is required for transduction with anti-CD30 phagemid particles and establishes the high specificity of these gene transfer particles. Incubation of the target cells with the M13-pAK8-Ki-4(EGFP) phagemid particles led to a maximum transduction rate of 5%, a rate approximately 10-fold higher compared to the M13-pC6-Ki-4(EGFP) phagemid particles. This enabled a direct comparison of pVIII- and pIII- fusion protein display for receptor-specific gene transfer. Although there is a postulated avidity effect responsible for the stronger binding of the M13-pAK8-Ki-4(EGFP) phagemid particles to recombinant CD30 and CD30-positive cells compared to the M13-pC6-Ki-4(EGFP) phagemid particles, this significant difference in transduction efficiency was somewhat surprising. Other groups using monovalent pIII-display with transduction efficiencies of 1–4% were able to increase the efficiencies up to 10% by using multivalent pIII-display [6, 9].
It has been described that CD30 receptor is being internalized by clathrin-mediated endocytosis, maturing to lysosomes and that cross-linking of CD30 receptors by monoclonal antibodies enhances this trafficking at least by 3-fold . In accordance with our results, this supports our hypothesis that pVIII-based display of scFvs is multivalent, leading to increased internalization and transduction efficiency of CD30-bearing cells. Although it has been shown that multivalent scFv-pIII display on bacteriophage is possible and increases transduction efficiency , our approach serves as an alternative or even superior system, especially if the internalization depends on multipoint 'zipper' contacts of the phage with the cell surface receptors. A multivalent display on pVIII may provide an increased binding and phage uptake because pVIII fusion proteins are spread over the surface of the phage, in contrast to pIII fusion proteins, which are focused on the tip of the phage. This so-called 'disseminated display' would also explain why M13-pAK8-Ki-4(EGFP), in contrast to the M13-pC6-Ki-4(EGFP) phagemid particles, are able to connect CD30-positive cells leading to cluster formation (Fig. 5). This also explains the stronger binding activity of the M13-pAK8-Ki-4(EGFP) phagemid particles (Fig. 4) and the higher transduction rate (Fig. 6d). However, this potential cross-linking of cells by single M13-pAK8-Ki-4(EGFP) phagemid particles does not prevent internalization of other M13-pAK8-Ki-4(EGFP) phagemid particles, because simultaneous binding of receptors on one cell is even more likely than cross linking of receptors on separate cells.
The feasibility of displaying molecules as large as scFvs (27 kDa) on the major coat protein raises the possibility of generating bispecific phagemid particles rescued from E. coli, encoding an additional pIII- or pVIII-fusion protein, thereby increasing specificity and avidity of the cell-targeting phagemid particle.
The unequal transduction rates of the different CD30-positive cell lines with the M13-pAK8-Ki-4(EGFP) phagemid particles are not directly explainable by their individual CD30 receptor densities. For example, cell line L1236 showed only a moderate binding of the anti-CD30 phagemid particles in FACS analysis compared to the L540 cell line(Fig. 4), but revealed the highest EGFP-expression rate (Fig. 6c). This demonstrates that the efficiency of the gene transfer seems to be dependent on cell line-specific trafficking of the bacteriophage after binding. Because the gene transfer efficiency of targeted bacteriophage is in general still very low, it seems to be necessary to further optimize trafficking, DNA processing and nuclear localization of the phagemid DNA. So far, satisfying transduction rates (30–45%) with bacteriophage have been reached only in vitro by genotoxic treatment .
To our knowledge, this is the first approach demonstrating a potential advantage of the major coat protein pVIII as fusion partner for the display of scFvs in gene transfer experiments, compared to the commonly used minor coat protein pIII. Furthermore, it is the first approach generating a CD30-specific gene transfer vector to be used for the transduction of Hodgkin-, Reed Sternberg cells. A possible application of this system would be the specific induction of apoptosis in these cells. It is believed that cancer cells are on the verge of apoptosis, containing processed effector caspases. At the same time, they also express inhibitor of apoptosis proteins (IAPs), which can not be neutralized due to malfunctioning apoptotic pathways . It has been demonstrated that overexpression of second mitochondrial activator of caspases (SMAC) in Hodgkin-derived cell lines blocks X-linked IAPs activation , and therefore would make a promising candidate gene for restoration of the apoptotic pathway in Hodgkin's disease via targeted gene therapy. Provided that the transduction efficiency of CD30-specific bacteriophage is further increased by additional molecular modifications, they can potentially serve as specific, safe, cheap and efficient gene therapy vectors for in and ex vivo applications. This is supported by the fact that tumor treatment with targeted bacteriophage in vivo has been demonstrated recently .
Cells and Bacteria
The Morbus Hodgkin derived cell lines L540 , L1236 , L428 , KMH-2 , the Burkitt lymphoma cell line BL38  and the multiple myeloma cell line U266  were cultivated in RPMI 1640 supplemented with 10% (v/v) heat inactivated fetal calf serum (FCS), 50 μg/ml Penicillin, 100 μg/ml Streptomycin and 2 mM L-glutamine. All cells were cultured at 37°C in a 5% CO2 atmosphere. E. coli TG-1 (K12 Δ(lac-pro), sup E, thi, hsd D5F'tra D36, proA+B+, lacI q, lacZ ΔM15) were provided by CAT (Cambridge, UK).
pAK8 was cloned by exchanging the minor coat protein pIII gene from pCANTAB6-Ki-4 phagemid vector  with the major coat protein pVIII gene from KM13-K07 helper phage genome. pVIII was amplified by PCR using the primer pair pVIII NotI sense 5'-ATC GCG GCC GCA GAG GGT GAC CCC-3' and pVIII EcoRI antisense 5'-ACT GAA TTC TTA TCA GCT TGC TTT-3'. The PCR product was digested with Not I/Eco RI and ligated into pCANTAB6-Ki4 phagemid vector. pAK8-Ki-4 and pCANTAB6-Ki-4 phagemid vectors were digested with restriction enzyme EheI creating blunt ends and ligated with the reporter gene cassette CMV-EGFP, obtained from pEGFP-N3 plasmid (Clontech, USA) that had been digested with VspI/BspT1 and treated with T4 DNA polymerase to produce blunt ends. The resulting phagemid vectors were pAK8-Ki-4(EGFP) and pC6-Ki-4(EGFP). The control phagemid vector pAK8(EGFP) was constructed by excising the Ki-4 scFv gene via Pvu II digest.
Phagemid particle preparation and purification
For production of M13-pAK8-Ki4(EGFP), M13-pC6-Ki4(EGFP) and M13-pAK8(EGFP) phagemid particles, phagemid vector transformed overnight culture of E. coli TG-1 were grown and used to inoculate 50 ml 2xYT + 100 μg/ml ampicillin at a ratio of 1:100 at 37°C with vigorous shaking (220 rpm) to an OD600 of 0.5. 5 ml of the culture were infected with helper phage (KM13-K07) at a ratio of 4 phage per bacterium and incubated at 37°C in a water bath without shaking for 30 min and 30 min at 37°C with shaking (220 rpm). Bacteria were spun down, resuspended in 25 ml 2xYT + 100 μg/ml ampicillin + 50 μg/ml kanamycin and shaken overnight at 30°C. After removing of bacteria by centrifugation (20 min at 4400 g) supernatant was transferred into fresh bottles and phage were purified by two rounds of standard polyethylene glycol (PEG) precipitation as described . The final phage pellet was resuspended in 1.5 ml PBS. Phage titers in colony forming units (cfu) were determined by photometrical absorption at 269 nm as described .
Multi-well Maxisorp plates (Nunc, Germany) were coated for 1 h at room temperature with 50 μl of recombinant CD30 antigen (R&D Systems, USA) at a concentration of 10 μg/ml in bicarbonate buffer, pH 9.6. After discarding the coating solution, wells were washed 5 × with 200 μl PBS-0.1% Tween and incubated for 1 h with blocking solution (PBS-4% skimmed milk powder). After washing, 50 μl of M13-pAK8-Ki-4(EGFP), M13-pC6-Ki-4(EGFP) and M13-pAK8(EGFP) phagemid particles (4 × 1010 cfu) were added to the wells and allowed to bind for one hour. Plates were washed 10 × with 200 μl PBS-0.1% Tween and 50 μl of a 10 μg/ml solution of anti-M13-pVIII-HRP-conjugated antibody (Amersham, USA) in blocking buffer was added to each well and incubated for 1 h. Plate was washed and horseradish peroxidase activity was detected by incubation with 50 μl OPD-substrate (Pierce, USA) and reaction was stopped by adding 25 μl H2SO4 (1N). Substrate conversion was read by an automated ELISA reader and the results were expressed as A = A492 nm-A620 nm.
SDS-PAGE and Western Blot Analysis
25 μl of purified phage samples (5 × 1012 particles/ml) per lane were separated by 14% SDS-PAGE and transferred to a nitrocellulose membrane using a Mini Protean III Blotting unit (BioRad, Germany) at 250 mA for 90 min. Membrane was blocked with blocking buffer for 1 h, washed 3 × for 5 min with PBS, then anti-M13-pVIII antibody solution (1 μg/ml) in blocking buffer was added and incubated for 1 h at RT with gentle shaking. Membrane was washed 3 times and goat-anti-mouse-HRP-conjugated antibody in blocking buffer (1 μg/ml) was added followed by 1 h incubation at RT. After washing three times with PBS Western Blots were developed using the CN/DAB substrate kit (Pierce).
FACS analysis of phagemid particles binding to cell lines
Cells (5 × 105) were washed twice with 1 ml FACS wash buffer (PBS, 2% FCS, 0.1% NaN3) by centrifugation (300 g) and incubated with 5 × 109 phagemid particles in 100 μl for 1 h at 4°C. Cells were washed twice as described above and incubated with 100 ng murine anti-M13 antibody (Progen, Germany) in 100 μl. Cells were washed twice and incubated with 200 ng Alexa Fluor 488-conjugated goat anti-mouse antibody (Invitrogen, Germany) in 50 μl. Cells were washed and analyzed for green fluorescence using a Becton Dickinson FACScanto cytometer and Becton Dickinson FACSDiva software.
Cells were seeded at 5 × 104/well in 12-well plates in complete medium and 500 μl phage suspension (4 × 1012 phagemid particles/ml) was added to a total volume of 1.5 ml and incubated for 48 h. After 48 h 1 ml complete medium was added and cells were incubated for additional 48 h. EGFP expression was determined by flow cytometry. To determine the significance of the data, statistical analysis were performed according to the Student's one-tailed t test. p-values < 0.05, < 0.01 and < 0.001 were indicated with *, ** or ***, respectively. For the competition assay 5 × 104 L1236 cells per well were incubated with 2 × 1011 M13-pAK8-Ki-4(EGFP) phagemid particles in the absence or presence of 30 nM or 300 nM of the parental monoclonal antibody Ki-4. After 96 hours cells were analyzed for EGFP expression by fluorescence microscopy.
The authors thank Janina Lamberz for excellent technical assistance. This work was supported, in part, by the Leibniz-Preis 2001 (KR-810/14-1 DFG3622/383/11) and the Koeln Fortune Program/Faculty of Medicine, University of Cologne.
- Piersanti S, Cherubini G, Martina Y, Salone B, Avitabile D, Grosso F, Cundari E, Di Zenzo G, Saggio I: Mammalian cell transduction and internalization properties of lambda phages displaying the full-length adenoviral penton base or its central domain. J Mol Med 2004, 82: 467-476. 10.1007/s00109-004-0543-2View ArticlePubMedGoogle Scholar
- Larocca D, Witte A, Johnson W, Pierce GF, Baird A: Targeting bacteriophage to mammalian cell surface receptors for gene delivery. Hum Gene Ther 1998, 9: 2393-2399. 10.1089/hum.1998.9.16-2393View ArticlePubMedGoogle Scholar
- Hoogenboom HR, Marks JD, Griffiths AD, Winter G: Building antibodies from their genes. Immunol Rev 1992, 130: 41-68. 10.1111/j.1600-065X.1992.tb01520.xView ArticlePubMedGoogle Scholar
- Ivanenkov VV, Felici F, Menon AG: Targeted delivery of multivalent phage display vectors into mammalian cells. Biochim Biophys Acta 1999, 1448: 463-472. 10.1016/S0167-4889(98)00163-3View ArticlePubMedGoogle Scholar
- Becerril B, Poul MA, Marks JD: Toward selection of internalizing antibodies from phage libraries. Biochem Biophys Res Commun 1999, 255: 386-393. 10.1006/bbrc.1999.0177View ArticlePubMedGoogle Scholar
- Poul MA, Marks JD: Targeted gene delivery to mammalian cells by filamentous bacteriophage. J Mol Biol 1999, 288: 203-211. 10.1006/jmbi.1999.2678View ArticlePubMedGoogle Scholar
- Mount JD, Samoylova TI, Morrison NE, Cox NR, Baker HJ, Petrenko VA: Cell targeted phagemid rescued by preselected landscape phage. Gene 2004, 341: 59-65. 10.1016/j.gene.2004.07.006View ArticlePubMedGoogle Scholar
- Kassner PD, Burg MA, Baird A, Larocca D: Genetic selection of phage engineered for receptor-mediated gene transfer to mammalian cells. Biochem Biophys Res Commun 1999, 264: 921-928. 10.1006/bbrc.1999.1603View ArticlePubMedGoogle Scholar
- Larocca D, Jensen-Pergakes K, Burg MA, Baird A: Receptor-targeted gene delivery using multivalent phagemid particles. Mol Ther 2001, 3: 476-484. 10.1006/mthe.2001.0284View ArticlePubMedGoogle Scholar
- Ivanenkov V, Felici F, Menon AG: Uptake and intracellular fate of phage display vectors in mammalian cells. Biochim Biophys Acta 1999, 1448: 450-462. 10.1016/S0167-4889(98)00162-1View ArticlePubMedGoogle Scholar
- Iannolo G, Minenkova O, Petruzzelli R, Cesareni G: Modifying filamentous phage capsid: limits in the size of the major capsid protein. J Mol Biol 1995, 248: 835-844. 10.1006/jmbi.1995.0264View ArticlePubMedGoogle Scholar
- Malik P, Terry TD, Gowda LR, Langara A, Petukhov SA, Symmons MF, Welsh LC, Marvin DA, Perham RN: Role of capsid structure and membrane protein processing in determining the size and copy number of peptides displayed on the major coat protein of filamentous bacteriophage. J Mol Biol 1996, 260: 9-21. 10.1006/jmbi.1996.0378View ArticlePubMedGoogle Scholar
- Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, Schindler J, Ghetie V, Vitetta ES, Diehl V, Engert A: A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res 2002, 8: 1779-1786.PubMedGoogle Scholar
- Klimka A, Barth S, Matthey B, Roovers RC, Lemke H, Hansen H, Arends JW, Diehl V, Hoogenboom HR, Engert A: An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line. Br J Cancer 1999, 80: 1214-1222. 10.1038/sj.bjc.6690488PubMed CentralView ArticlePubMedGoogle Scholar
- Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, Lewis TS, Meyer DL, Zabinski RF, Doronina SO, Senter PD, Law CL, Wahl AF: Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 2006, 281: 10540-10547. 10.1074/jbc.M510026200View ArticlePubMedGoogle Scholar
- Burg MA, Jensen-Pergakes K, Gonzalez AM, Ravey P, Baird A, Larocca D: Enhanced phagemid particle gene transfer in camptothecin-treated carcinoma cells. Cancer Res 2002, 62: 977-981.PubMedGoogle Scholar
- Bremer E, van Dam G, Kroesen BJ, de Leij L, Helfrich W: Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends Mol Med 2006, 12: 382-393. 10.1016/j.molmed.2006.06.002View ArticlePubMedGoogle Scholar
- Kashkar H, Seeger JM, Hombach A, Deggerich A, Yazdanpanah B, Utermohlen O, Heimlich G, Abken H, Kronke M: XIAP targeting sensitizes Hodgkins Lymphoma cells for cytolytic T cell attack. Blood 2006, 108(10):3434-40. 10.1182/blood-2006-05-021675View ArticlePubMedGoogle Scholar
- Hajitou A, Trepel M, Lilley CE, Soghomonyan S, Alauddin MM, Marini FC 3rd, Restel BH, Ozawa MG, Moya CA, Rangel R, Sun Y, Zaoui K, Schmidt M, von Kalle C, Weitzman MD, Gelovani JG, Pasqualini R, Arap W: A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 2006, 125: 385-398. 10.1016/j.cell.2006.02.042View ArticlePubMedGoogle Scholar
- Kapp U, Wolf J, von Kalle C, Tawadros S, Rottgen A, Engert A, Fonatsch C, Stein H, Diehl V: Preliminary report: growth of Hodgkin's lymphoma derived cells in immune compromised mice. Ann Oncol 1992, 3 Suppl 4: 21-23.View ArticlePubMedGoogle Scholar
- Wolf J, Kapp U, Bohlen H, Kornacker M, Schoch C, Stahl B, Mucke S, von Kalle C, Fonatsch C, Schaefer HE, Hansmann ML, Diehl V: Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood 1996, 87: 3418-3428.PubMedGoogle Scholar
- Schaadt M, Diehl V, Stein H, Fonatsch C, Kirchner HH: Two neoplastic cell lines with unique features derived from Hodgkin's disease. Int J Cancer 1980, 26: 723-731. 10.1002/ijc.2910260605View ArticlePubMedGoogle Scholar
- Kamesaki H, Fukuhara S, Tatsumi E, Uchino H, Yamabe H, Miwa H, Shirakawa S, Hatanaka M, Honjo T: Cytochemical, immunologic, chromosomal, and molecular genetic analysis of a novel cell line derived from Hodgkin's disease. Blood 1986, 68: 285-292.PubMedGoogle Scholar
- Lenoir GM, Vuillaume M, Bonnardel C: The use of lymphomatous and lymphoblastoid cell lines in the study of Burkitt's lymphoma. IARC Sci Publ 1985, 309-318.Google Scholar
- Drexler HG, Matsuo Y: Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia. Leuk Res 2000, 24: 681-703. 10.1016/S0145-2126(99)00195-2View ArticlePubMedGoogle Scholar
- Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G: By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991, 222: 581-597. 10.1016/0022-2836(91)90498-UView ArticlePubMedGoogle Scholar
- Day LA, Wiseman RL, Marzec CJ: Structure models for DNA in filamentous viruses with phosphates near the center. Nucleic Acids Res 1979, 7: 1393-1403. 10.1093/nar/7.6.1393PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.